NCT07047586View on ClinicalTrials.gov

Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab

PHASE2RecruitingINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

July 2, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
DRUG

Tislelizumab

Tislelizumab will be administered by IV, 200 mg on day 1 of each 21 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

DRUG

Lenvatinib

Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

Trial Locations (1)

200032

RECRUITING

Zhongshan Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT07047586 - Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab | Biotech Hunter | Biotech Hunter